A Study to Evaluate Iloperidone Long-acting Injection (LAI) for the Treatment of Schizophrenia

NCT04712734 PHASE1 COMPLETED

This is a multicenter, open-label, adaptive, repeat-dose study to evaluate the safety, tolerability, and pharmacokinetics of iloperidone long-acting injection (LAI) in patients with schizophrenia.

Details

Lead sponsor	Vanda Pharmaceuticals
Phase	PHASE1
Status	COMPLETED
Enrolment	42
Start date	Wed Jan 13 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue Aug 30 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Schizophrenia

Interventions

• Iloperidone

Countries

United States